Top Injectable Manufacturer in Bahrain – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 1 day ago
- 11 min read
Last Updated: September 5, 2026
TL;DR: Bahrain answers the question we always ask first — does the country keep a list of regulators it will rely on, and is India on it — with a clear yes and a clear no. The National Health Regulatory Authority's Medicine Licensing Guideline of 20 October 2025 names six fast-track reference authorities (the Gulf Health Council's central registration, SFDA, US FDA, EMA, Swissmedic and MHRA), a second list on its application form, a third list of GMP 'competent authorities' for licensing foreign sites and a nineteen-country pricing basket, and India's CDSCO is on none of them. Absence is not exclusion: the normal 45-working-day pathway is open to any origin that can furnish a legalised WHO-format CPP, a home-regulator GMP certificate, one year of home-market sales, an eCTD dossier and samples for NHRA laboratory testing. The hard knot is site licensing, which as written wants GHC site registration or a Western or Japanese GMP certificate — for a sterile product, for both bulk manufacturer and batch releaser. The commercial gate is consolidating under the Supreme Council of Health's unified-procurement committee, with the Health Insurance Fund as the government's importer.
Key Takeaways
A named list, and India is not on it. Fast-track registration in ten working days requires prior approval by the GHC central committee, SFDA, US FDA, EMA, Swissmedic or MHRA; the application form separately asks whether the product is licensed by the GHC, US FDA, Health Canada, TGA, EMA or nine European agencies. There is no WHO-prequalification or generic stringent-authority clause to argue under, and the WHO's August 2026 maturity list places CDSCO at level 3 for vaccines only.
The normal pathway is a certificate test. Forty-five working days; a legalised WHO-format CPP from the batch-releaser's country; a country-of-origin GMP certificate; at least one year on the home market; an eCTD dossier to GHC and ICH structure; NHRA laboratory analysis before first import — 50 ampoules, 25 vials or 20 prefilled syringes; a five-year licence cancelled if the product is not marketed within two. A licensed Bahraini pharmacy acts as local agent; the distributor cannot be the marketing-authorisation holder.
Site licensing is the knot. Before any product application the foreign site needs an NHRA licence, and checklist item 12 asks for a GHC site-registration certificate or, failing that, a GMP certificate from one of eleven authorities — EudraGMP, Ireland, Germany, France, MHRA, US FDA, Health Canada, TGA, Medsafe, Swissmedic or Japan — beside the home-country GMP certificate; sterile products need licences for both bulk manufacturer and batch releaser. Whether NHRA accepts alternatives in practice we could not verify, so the practical Indian route begins with GHC site registration.
Price is set by a basket India is not in. The generic CIF price is the lowest of origin ex-factory plus freight, the lowest CIF in Kuwait, Oman, Qatar, Saudi Arabia, the UAE, Egypt, Jordan, Turkey and eleven Western markets, the price of similar registered drugs, or a ladder that cuts each successive generic; CIF is fixed in US dollars at 0.377 dinars. Buyers are consolidating under the Supreme Council of Health's unified-procurement committee, and adult diabetes prevalence was 22.1% in 2024.
Introduction: Why Bahrain Demands a Premium Injectable Manufacturer in Bahrain
Every market in this series opens with the same question: does the country publish a list of regulatory authorities whose decisions it will lean on, and is India's CDSCO among them? Bahrain, the first Gulf market in the series, answers with unusual precision, because the National Health Regulatory Authority writes its lists down. The operative text is the NHRA Medicine Licensing Guideline, version 4.1 of 20 October 2025, which we read in full. Its fast-track pathway — ten working days against forty-five for the normal route — is open only to products already approved by the Gulf Health Council's central registration, Saudi Arabia's SFDA, the US FDA, the EMA, Swissmedic or the UK's MHRA, with the batch-release site registered with one of them. The application form asks separately whether the product is licensed by the GHC, the US FDA, Health Canada, the TGA, the EMA or the agencies of nine European countries, and the bioequivalence-centre rule accepts GHC-approved sites or those approved by the WHO, US FDA, Health Canada, TGA, MHRA or EMA. India appears in none of these lists, and there is no WHO-prequalification clause, no maturity-level clause and no generic stringent-authority clause anywhere in the guideline under which an Indian approval might be argued in.
So the answer to the standing question is a plain no, and the more useful question is what the no costs. It does not cost market access. The normal pathway does not discriminate by country of origin; what it demands is paper and product: a WHO-format certificate of a pharmaceutical product, legalised and issued in the batch-releaser's country, a GMP certificate from that country's health authority, proof that the medicine has been marketed at home for at least one year, an eCTD dossier to the GHC and ICH common technical document, and samples for mandatory laboratory analysis before the first importation — 50 ampoules, 25 vials, 20 prefilled syringes or 5 units of a small-volume solution, with reference standards and full methods — quantities the guideline itself calls approximate and subject to change. A licence runs five years and is cancelled if the product is not marketed within two. The fee schedule sits in a 2016 resolution we could not fetch, so the only figure we print is the 50-dinar hospital-pack fee. A premium injectable manufacturer in Bahrain, then, treats the certificate test as a discipline rather than a formality — and solves the site-licensing problem before filing a single product.
What Sets a World-Class Injectable Manufacturer in Bahrain Apart
The site-licensing problem is the real gate. NHRA's International Manufacturing Site Licensing Procedure, version 1.6 of the same October 2025 date, makes licensing of the foreign manufacturing site mandatory before any product application. Item 12 of its checklist asks for a valid Gulf Health Council site-registration certificate or, if the applicant cannot supply one, a GMP certificate from a named competent authority — EudraGMP, Ireland's HPRA, Germany, France's ANSM, the MHRA, the US FDA, Health Canada, the TGA, New Zealand's Medsafe, Swissmedic or Japan's health ministry — and item 13 separately requires the GMP certificate of the country of origin. For sterile formulations both the bulk manufacturer and the batch releaser must hold NHRA site licences. The licence is assessed in thirty working days, runs five years and lapses if no product is registered within three. As written, an Indian site with only Indian GMP certification cannot satisfy item 12; whether NHRA exercises discretion in practice we could not verify and do not assert. The honest consequence is that the Indian route to Bahrain begins in Riyadh rather than Manama: with the GHC's central registration committee, created by the Gulf health ministers in 1998, which inspects factories and registers companies under unified regulations, and whose registration Bahrain accepts as a fast-track reference, as a substitute for the CPP and as a substitute for the competent-authority GMP certificate.
Two further layers deserve care. First, the GHC's own reference-authority text was not obtained; the only description we found is a 2022 academic evaluation, based on GHC data, reporting that a product approved by two Gulf states or by the US FDA, the EMA or WHO prequalification receives an abridged review, that reliance began at the end of 2019, and that generics are within scope. We report that as the literature's account, not the GHC's rule. Second, the pricing regime. Annex IV of the licensing guideline and the Medicine Pricing Guideline of January 2022 require prices in Kuwait, Oman, Qatar, Saudi Arabia and the UAE and in Australia, Belgium, Canada, Denmark, Egypt, France, Germany, Ireland, Jordan, Spain, Sweden, Switzerland, Turkey and the UK, plus the country-of-origin prices. A generic's CIF price is the lowest of four figures: origin ex-factory plus freight, the lowest CIF anywhere in the basket, the price of similar registered products, or a ladder under which the innovator drops 20% on first generic entry and each successive generic is priced 15%, then 10%, below the one before. CIF is fixed in US dollars at 0.377 dinars, retail is 1.35 times CIF up to 20 dinars and 1.25 above, and prices are revisited at renewal and whenever the home-market price falls. An Indian ex-factory price therefore sets a ceiling, never a floor.
Quality Systems Behind Every Injectable Supplied to Bahrain
For a sterile injectable the evidence an assessor or inspector expects is the same in Manama as anywhere: aseptic process simulation records for the ISO Class 5 filling line, environmental monitoring trends, container-closure integrity, sterility and bacterial endotoxin testing by LAL, particulate matter, validated HPLC and GC assay and impurity methods, and ICH Q1A and Q1B stability data for a hot, humid Gulf climate under the GCC stability guideline NHRA cites. Because analysis by an NHRA-authorised laboratory is mandatory before the first import and a second failure means rejection, the certificate of analysis, reference standards and methods that accompany the samples must be written to be reproduced by a laboratory that has never seen the product.
The international layers are quickly stated. Bahrain's NHRA does not appear on the WHO's August 2026 list of authorities at maturity level 3 or 4; the only Gulf authority on it is Saudi Arabia's SFDA, at level 4. India's CDSCO appears on that list for vaccines only, so even a generic maturity-level clause would not carry a small-molecule injectable from India, and Bahrain has no such clause in any case. Neither Bahrain nor India is a PIC/S participating authority. The Indian Pharmacopoeia Commission's recognition list of 10 July 2026 names twenty-four countries and no Gulf state, and the NHRA form asks for the pharmacopoeial standard of each ingredient, so the file should cite the USP, BP or Ph. Eur. monograph where one exists. The founding law, No. 38 of 2009, has not been superseded; Decree-Law 12 of 2023 amended it to move narcotic and psychotropic licensing to NHRA. The leaflet must be supplied in Arabic and English and the SmPC in English.
Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry.
Why Farbe Firma is the Trusted Injectable Manufacturer in Bahrain for Global Buyers
Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than thirty countries, among them Gulf and Middle Eastern markets where the GHC eCTD structure and GCC stability conditions are the working standard. We build dossiers in CTD and ACTD format, which is the structure NHRA requires in eCTD, and we supply the WHO-format certificate of a pharmaceutical product, the manufacturing licence and the GMP certificate as a matter of course. Because the guideline requires import and distribution through a licensed Bahraini pharmacy acting as local agent under a legalised contract, our route is a named pharmacy-agent in Bahrain, GHC site registration for the sterile line as the first regulatory act, and a price file built from the basket rather than from our list price.
The bilateral relationship is large and the pharmaceutical line in it is new. The Ministry of External Affairs brief of June 2024 records bilateral trade of USD 1,738.86 million in 2023–24, with Indian exports of USD 909.42 million, and names 'medicaments' among India's exports as a recent addition, beside rice, meat, sugar, machinery, jewellery and polymers. There is a health instrument: a memorandum on cooperation in healthcare signed in July 2018, under which an India–Bahrain Joint Working Group on Healthcare first met on 22 February 2022; NHRA's chief executive attended Pharmexcil's iPHEX and regulators' conclave in New Delhi in September 2022. We found no agreement between NHRA and CDSCO. Reports of the fifth High Joint Commission in New Delhi on 3 November 2025 say the two sides agreed to begin negotiating a comprehensive economic partnership agreement; no such agreement exists yet. UN Comtrade's public preview returns Indian pharmaceutical exports to Bahrain of about USD 8.7 million in 2024 and USD 9.4 million in 2025, but flags every record as an estimate, so we quote the order of magnitude and nothing finer. The Indian community, which the two MEA briefs put at 340,000 and 350,000, is roughly a quarter of the population.
Where the money is: Bahrain has 1.60 million people, gross national income per capita of USD 28,790 in 2025, current health expenditure of about USD 1,176 per person and 4.0% of GDP in 2023, and life expectancy of 81.4 years. Out-of-pocket payments were 28.7% of health expenditure in 2023 and rising, and diabetes prevalence among adults was 22.1% in 2024, up from 19.5% in 2011; the UNDP investment case for Bahrain is reported to attribute three quarters of deaths to the four main non-communicable diseases. Public purchasing is being consolidated under the Supreme Council of Health, whose National Committee for Unified Procurement of Medicines and Medical Supplies approves purchase contracts, holds the strategic national stock and prepares the essential-medicines list, and whose membership names the buyers: the Health Insurance Fund as vice-chair and, per the health minister's 2024 statement, the government's importer of record; King Hamad University Hospital; the Bahrain Defence Force Hospital; the Bahrain Oncology Center; the specialist cardiac centre; the government hospitals; and primary care. Ministry of Health tenders are advertised through the Tender Board portal, and the committee's brief includes increasing Bahrain's share of the GCC Joint Procurement Programme, whose 2026 tender schedule is published and whose supplier prerequisites we could not obtain. Hospital pack sizes supplied to tenders must be registered with NHRA, and injectable hospital packs of one to ten units are not accepted unless they are at least five times the largest registered pack. The national health insurance law of 2018 is the frame for all of it; the pace of its rollout in 2026 we report only as claimed.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is India on Bahrain's list of recognised regulatory authorities?
No. NHRA's Medicine Licensing Guideline of 20 October 2025 names the GHC central registration, SFDA, US FDA, EMA, Swissmedic and MHRA as fast-track reference authorities, lists the GHC, US FDA, Health Canada, TGA, EMA and nine European agencies on its application form, and lists eleven Western and Japanese authorities as GMP 'competent authorities' for site licensing; CDSCO is on none, and there is no WHO-prequalification or maturity-level clause. Absence is not exclusion: the normal 45-working-day pathway accepts a legalised WHO-format CPP and GMP certificate from India once the site is licensed by NHRA.
What law governs medicine registration in Bahrain?
Decree-Law 18 of 1997 on the practice of pharmacy, amended by Decree-Law 20 of 2015, with Resolution 63 of 2019 and the Supreme Council of Health's registration and pricing regulation, Resolution 32 of 2020 as amended by Resolution 46 of 2023; NHRA itself was created by Law 38 of 2009, amended by Decree-Law 12 of 2023. The operative rules are NHRA's Medicine Licensing Guideline version 4.1 and Site Licensing Procedure version 1.6, both of 20 October 2025, and the Pricing Guideline of January 2022. Dossiers are eCTD; licences run five years; fees follow Decree 17 of 2016, whose schedule we could not fetch.
Can an Indian manufacturer get its site licensed by NHRA?
As written, only with a Gulf Health Council site-registration certificate or a GMP certificate from one of eleven listed authorities — EudraGMP, Ireland, Germany, France, the MHRA, US FDA, Health Canada, TGA, Medsafe, Swissmedic or Japan — in addition to the Indian GMP certificate. Whether NHRA accepts alternatives in practice we could not verify. For a sterile product both the bulk manufacturer and the batch releaser need licences. The practical sequence is GHC site registration first, then the NHRA site licence, then the product.
Who buys injectables in Bahrain?
Government purchasing is consolidating under the Supreme Council of Health's National Committee for Unified Procurement, with the Health Insurance Fund as the government's importer and King Hamad University Hospital, the Bahrain Defence Force Hospital, the Bahrain Oncology Center, the cardiac centre, the government hospitals and primary care at the table; Ministry of Health tenders are advertised through the Tender Board portal, and Bahrain takes part in the GCC Joint Procurement Programme. Every product reaches the market through a licensed Bahraini pharmacy as local agent, and hospital pack sizes must be registered with NHRA before they can be tendered.
Does Farbe Firma have experience with GCC markets?
Yes. Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries, including Gulf and Middle Eastern markets. We prepare dossiers in CTD and ACTD format to the GHC and ICH eCTD structure, generate stability data under GCC conditions, supply the WHO-format CPP, manufacturing licence and GMP certificate, and work through licensed local agents with Arabic and English leaflets. Write to director@farbefirma.org with the product list and we will map it to the NHRA pathway and the pricing basket.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments